A Better Way to Think About Adult RSV Vaccination

Adult RSV vaccination is becoming more risk-stratified because one question—who is old enough—no longer captures the decision’s relevant variables. Age identifies a broad gradient of vulnerability, but medical conditions, immune status, care setting, time since vaccination, product evidence, and safety signals also shape the balance of benefit and uncertainty. The final judgment of this series is that risk stratification is an adaptive way to allocate protection under incomplete evidence, not a promise that medicine can reduce every person to a precise risk score.

The decision has five connected parts

A useful way to understand the current policy is to keep five questions connected rather than ask only whether an adult qualifies by age.

The first is baseline severity risk. RSV is not equally consequential for every adult. Older age, chronic heart or lung disease, immune compromise, frailty, residence in a nursing home, and circumstances that make escalation of care difficult can increase the chance or consequences of severe illness. That is why CDC recommends one dose for all adults aged 75 years or older, while using an increased-risk recommendation for adults aged 50–74. The younger group is not treated as a single block because age alone is a less complete proxy for severe disease at that range.

The second is expected vaccine protection. The two-season study found an estimated 58% effectiveness against RSV-associated hospitalization among adults aged 60 years or older. That is meaningful evidence for a serious outcome, but it is an average from a hospitalized surveillance population, not a personal forecast. In the same study, effectiveness was lower among adults with moderate or severe immunocompromise and among immunocompetent adults with cardiovascular disease than in their respective comparison groups. Those differences matter because a policy that focuses on high-risk adults must ask not only who is most vulnerable, but also how reliably a dose protects them.

The third is time. A dose given before the season of illness may not have the same observed effectiveness as a dose received in the prior season. The study estimated 69% effectiveness for same-season vaccination and 48% for prior-season vaccination, but the difference was not statistically significant. The pattern supports continued surveillance of durability; it does not establish a fixed decline or tell clinicians that a booster is due each year.

The fourth is practical delivery. CDC says eligible adults may be vaccinated at any time, with late summer or early fall usually preferred so protection is in place before the usual RSV season. CDC also lists three licensed adult vaccines and expresses no preference among a licensed and available option. Availability, timing, the feasibility of returning for another visit, and coadministration with other vaccines are practical parts of the decision, not afterthoughts.

The fifth is safety. FDA required a GBS warning for Abrysvo and Arexvy after postmarketing evidence suggested an increased risk during the 42 days after vaccination. The estimated excess was approximately 9 cases per million Abrysvo doses and 7 per million Arexvy doses among Medicare beneficiaries aged 65 years or older. FDA also said the evidence was insufficient to establish causality and that the benefits of both vaccines continued to outweigh their risks. A responsible decision therefore includes safety monitoring without treating a signal as either proof of harm or a reason to ignore it.

These parts form a policy loop rather than a one-time verdict:

flowchart TD A["Age and increased-risk assessment"] --> B["Expected severity and likely benefit of one dose"] B --> C["Seasonal delivery and licensed product availability"] C --> D["Monitor hospitalization and severe outcomes"] D --> E["Monitor durability, subgroup performance, and safety"] E --> F{"Material evidence change or unresolved gap?"} F -->|No| G["Continue current one-dose policy; no automatic annual repeat"] F -->|Yes| H["Update recommendation or future-dose policy"] H --> C

The loop explains why “risk-stratified” should not be confused with “finalized.” The current recommendation acts on the best available balance of risk and benefit, while surveillance tests whether that balance changes. A policy can remain stable while evidence becomes more precise, or it can change when a new result is large, consistent, and relevant enough to justify a different threshold or dosing interval.

Why age remains important without being sufficient

Risk stratification does not discard age. CDC’s universal recommendation for adults aged 75 years or older recognizes that advancing age is itself associated with greater vulnerability to severe respiratory disease. It also avoids requiring an older adult or clinician to prove a particular diagnosis before considering vaccination.

Below age 75, however, a broader “older adult” category becomes less informative. CDC’s list of increased-risk conditions includes chronic cardiovascular and respiratory disease, kidney failure or dialysis, selected complications of diabetes, conditions that impair airway clearance or respiratory muscle strength, severe obesity, immune compromise, and nursing-home residence.